Dr. Venook is a Medical Oncologist with expertise in Gastrointestinal cancers. He leads that program in the UCSF Helen Diller Family Comprehensive Cancer Center. The program boasts a robust clinical trials portfolio primarily for patients in need of new options.
Awards & Honors
Award
Conferred By
Date
Giant of Cancer Care in GI Oncology
Giants of Cancer Care
2019
Heroes of Hope Award
Colon Cancer Alliance
2017
NCCN Board of Producers Award
National Comprehensive Cancer Network
2013
Service Excellence Award
Healthnetwork Foundation
2011
Director's Service Award
National Cancer Institute
2010
Education
Institution
Degree
Dept or School
End Date
University of California, San Francisco
M.D.
Medicine
1980
University of California, San Francisco
Residency
School of Medicine
Board Certifications
American Board of Internal Medicine American Board of Internal Medicine: Medical Oncology - Subspecialty American Board of Internal Medicine: Hematology - Subspecialty
Clinical Expertise
Anal Cancer Colon Cancer Esophageal Cancer Hepatocellular Carcinoma (Liver Cancer) Liver Metastases Lynch Syndrome Pancreatic Cancer Rectal Cancer Stomach Cancer
Related Conditions: Colorectal Cancer, Colon Cancer, Colorectal Tumor| Start Date:
Program Affiliations
UCSF Helen Diller Family Comprehensive Cancer Center GI Oncology Program The Liver Center at UCSF
Grants and Funding
Cancer Center Support Grant | NIH | 1999-08-05 - 2023-05-31 | Role: Co-Investigator
General Clinical Research Center | NIH | 1974-12-01 - 2009-03-31 | Role: Co-Investigator
CANCER AND LEUKEMIA GROUP B | NIH | 1993-07-28 - 2003-03-31 | Role: Principal Investigator
Research Interests
Anal Cancer Colon Cancer Hepatocellular Carcinoma (Liver Cancer) Liver Metastases Rectal Cancer
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 324
q-Diffusion leverages the full dimensionality of gene coexpression in single-cell transcriptomics.
Marmarelis MG, Littman R, Battaglin F, Niedzwiecki D, Venook A, Ambite JL, Galstyan A, Lenz HJ, Ver Steeg G| | View in PubMed
Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapies.
Yazdani A, Yazdani A, Mendez-Giraldez R, Pillonetto G, Samiei E, Hadi R, Lenz HJ, Venook A, Samiei A, Nixon A, Lucci J, Kopetz S, Bertagnolli M, Perou C, Innocenti F| | View in PubMed
HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405.
CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma.
Abou-Alfa GK, Geyer SM, Nixon AB, Innocenti F, Shi Q, Kumthekar P, Jacobson S, El Dika I, Yaqubie A, Lopez J, Huang B, Tang YW, Wen Y, Schwartz LH, El-Khoueiry AB, Knox JJ, Rajdev L, Bertagnolli MM, Meyerhardt JA, O'Reilly EM, Venook AP| | View in PubMed
Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.
Keenan BP, Sibley A, Zhang L, Westring AF, Velazquez AI, Bank EM, Bergsland EK, Boreta L, Conroy P, Daras M, Hermiston M, Hsu G, Paris PL, Piawah S, Sinha S, Sosa JA, Tsang M, Venook AP, Wong M, Yom SS, Van Loon K| | View in PubMed
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou FS, Innocenti F, Takeda H, Kubota Y, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, Jayachandran P, Algaze S, Soni S, Zhang W, Goldberg RM, Hall MJ, Scott AJ, Hwang JJ, Lou E, Weinberg BA, Marshall J, Goel S, Xiu J, Michael Korn W, Venook AP, Sunakawa Y, Lenz HJ| | View in PubMed
CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value.
Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, Wang J, Ou FS, Innocenti F, Mumenthaler SM, Jayachandran P, Kawanishi N, Lenz A, Soni S, Algaze S, Zhang W, Khoukaz T, Roussos Torres E, Seeber A, Abraham JP, Lou E, Philip PA, Weinberg BA, Shields AF, Goldberg RM, Marshall JL, Venook AP, Korn WM, Lenz HJ| | View in PubMed
Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy.
Yazdani A, Lenz HJ, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanof H, Hadi R, Samiei E, Venook AP, Ratain MJ, Rashid N, Vincent BG, Qu X, Wen Y, Kosorok M, Symmans WF, Shen JPYC, Lee MS, Kopetz S, Nixon AB, Bertagnolli MM, Perou CM, Innocenti F| | View in PubMed
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
Quintanilha JCF, Sibley AB, Liu Y, Niedzwiecki D, Halabi S, Rogers L, O'Neil B, Kindler H, Kelly W, Venook A, McLeod HL, Ratain MJ, Nixon AB, Innocenti F, Owzar K| | View in PubMed
DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
Innocenti F, Mu W, Qu X, Ou FS, Kabbarah O, Blanke CD, Venook AP, Lenz HJ, Rashid NU| | View in PubMed
Associations between the Gut Microbiota, Race, and Ethnicity of Patients with Colorectal Cancer: A Pilot and Feasibility Study.
Piawah S, Kyaw TS, Trepka K, Stewart AL, Mora RV, Stanfield D, Levine K, Van Blarigan EL, Venook A, Turnbaugh PJ, Nguyen T, Atreya CE| | View in PubMed
Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance).
Brown JC, Ma C, Shi Q, Zemla T, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Chang V, Goldberg RM, Venook AP, Blanke CD, O'Reilly EM, Shields AF, Meyerhardt JA| | View in PubMed
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database.
Ou FS, Ahn DH, Dixon JG, Grothey A, Lou Y, Kasi PM, Hubbard JM, Van Cutsem E, Saltz LB, Schmoll HJ, Goldberg RM, Venook AP, Hoff P, Douillard JY, Hecht JR, Hurwitz H, Punt CJA, Koopman M, Bokemeyer C, Fuchs CS, Diaz-Rubio E, Tebbutt NC, Cremolini C, Kabbinavar FF, Bekaii-Saab T, Chibaudel B, Yoshino T, Zalcberg J, Adams RA, de Gramont A, Shi Q| | View in PubMed
Variety of Fruit and Vegetables and Alcohol Intake are Associated with Gut Microbial Species and Gene Abundance in Colorectal Cancer Survivors.
Kyaw TS, Upadhyay V, Tolstykh I, Van Loon K, Laffan A, Stanfield D, Gempis D, Kenfield SA, Chan JM, Piawah S, Atreya CE, Ng K, Venook A, Kidder W, Turnbaugh PJ, Van Blarigan EL| | View in PubMed
Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance).
Wang QL, Ma C, Yuan C, Shi Q, Wolpin BM, Zhang Y, Fuchs CS, Meyer J, Zemla T, Cheng E, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Goldberg RM, Venook A, Blanke C, Shields AF, O'Reilly EM, Meyerhardt JA, Ng K| | View in PubMed
Barriers and confidence among colorectal and prostate cancer survivors participating in two behavioral intervention studies.
Liu VN, Zuniga KB, Paciorek A, Zhang L, Chan JM, Carroll PR, Van Loon K, Laffan A, Venook A, Van Blarigan EL, Kenfield SA| | View in PubMed
Flashback Foreword: IFL/FOLFOX/IROX in Advanced Colorectal Cancer and FOLFIRI and FOLFOX6 in Colorectal Cancer.
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.
Benson AB, D'Angelica MI, Abrams T, Abbott DE, Ahmed A, Anaya DA, Anders R, Are C, Bachini M, Binder D, Borad M, Bowlus C, Brown D, Burgoyne A, Castellanos J, Chahal P, Cloyd J, Covey AM, Glazer ES, Hawkins WG, Iyer R, Jacob R, Jennings L, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Ronnekleiv-Kelly S, Sahai V, Singh G, Stein S, Turk A, Vauthey JN, Venook AP, Yopp A, McMillian N, Schonfeld R, Hochstetler C| | View in PubMed
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).
Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, Ginos B, Mazza GL, Colgrove B, Chang G, Minasian L, Denicoff A, Thanarajasingam G, Musher B, George T, Venook A, Farma J, O'Reilly E, Meyerhardt JA, Shi Q, Schrag D| | View in PubMed
Preoperative Treatment of Locally Advanced Rectal Cancer.
Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, Goodman KA, McWilliams RR, Farma JM, George TJ, Kennecke HF, Shergill A, Montemurro M, Nelson GD, Colgrove B, Gordon V, Venook AP, O'Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Chang GJ, Mamon HJ| | View in PubMed
Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Hecht JR, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Williams G, Algieri F, Gurski L, Stehman K| | View in PubMed
Neoadjuvant Immunotherapy for Colorectal Cancer: Too Good to Be True?
Sexual function remains persistently low in women after treatment for colorectal cancer and anal squamous cell carcinoma.
Savoie MB, Paciorek A, Van Loon K, Anwar M, Atreya CE, Johnson PC, Kenfield SA, Laffan A, Levin AO, Smith JF, Stanfield D, Venook A, Zhang L, Van Blarigan EL, Rowen T| | View in PubMed
Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data.
Zack T, Losert KP, Maisel SM, Wild J, Yaqubie A, Herman M, Knox JJ, Mayer RJ, Venook AP, Butte A, O'Neill AF, Abou-Alfa GK, Gordan JD| | View in PubMed
Quality of life among colorectal cancer survivors participating in a pilot randomized controlled trial of a web-based dietary intervention with text messages.
Wang L, Langlais C, Kenfield SA, Van Loon K, Laffan A, Atreya CE, Chan JM, Zhang L, Allen IE, Miaskowski C, Fukuoka Y, Meyerhardt JA, Venook AP, Van Blarigan EL| | View in PubMed
Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases.
Fidelman N, Atreya CE, Griffith M, Milloy MA, Carnevale J, Cinar P, Venook AP, Van Loon K| | View in PubMed
Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.
Lee S, Ma C, Shi Q, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Lewis D, Tan B, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF, Meyerhardt JA| | View in PubMed
Association between adherence to the American Cancer Society Nutrition and Physical Activity Guidelines and stool frequency among colon cancer survivors: a cohort study.
Greenberg AL, Tolstykh IV, Van Loon K, Laffan A, Stanfield D, Steiding P, Kenfield SA, Chan JM, Atreya CE, Piawah S, Kidder W, Venook AP, Van Blarigan EL, Varma MG| | View in PubMed
Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292).
Kemeny MM, Zhao F, Forastiere AA, Catalano P, Hamilton SR, Miedema BW, Dawson NA, Weiner LM, Smith BD, Mason BA, Graziano SL, Gilman PB, Venook AP, Pinto HA, Whitehead RP, O'Dwyer PJ, Benson AB| | View in PubMed
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Jeck W, Johung KL, Kirilcuk N, Krishnamurthi S, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Gregory K, Gurski L| | View in PubMed
Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism.
Spanogiannopoulos P, Kyaw TS, Guthrie BGH, Bradley PH, Lee JV, Melamed J, Malig YNA, Lam KN, Gempis D, Sandy M, Kidder W, Van Blarigan EL, Atreya CE, Venook A, Gerona RR, Goga A, Pollard KS, Turnbaugh PJ| | View in PubMed
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer.
Johnson RM, Qu X, Lin CF, Huw LY, Venkatanarayan A, Sokol E, Ou FS, Ihuegbu N, Zill OA, Kabbarah O, Wang L, Bourgon R, de Sousa E Melo F, Bolen C, Daemen A, Venook AP, Innocenti F, Lenz HJ, Bais C| | View in PubMed
Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).
Raghav K, Ou FS, Venook AP, Innocenti F, Sun R, Lenz HJ, Kopetz S| | View in PubMed
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, Ahmad S, Marsh R, Schwartz L, Behr S, Frankel WL, Collisson E, Leenstra J, Williams TM, Vaccaro G, Venook A, Meyerhardt JA, O'Reilly EM| | View in PubMed
Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405.
Van Blarigan EL, Ma C, Ou FS, Bainter TM, Venook AP, Ng K, Niedzwiecki D, Giovannucci E, Lenz HJ, Polite BN, Hochster HS, Goldberg RM, Mayer RJ, Blanke CD, O'Reilly EM, Ciombor KK, Meyerhardt JA| | View in PubMed
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab.
Innocenti F, Yazdani A, Rashid N, Qu X, Ou FS, Van Buren S, Bertagnolli MM, Kabbarah O, Blanke CD, Venook AP, Lenz HJ, Vincent BG| | View in PubMed
Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
Lipsyc-Sharf M, Zhang S, Ou FS, Ma C, McCleary NJ, Niedzwiecki D, Chang IW, Lenz HJ, Blanke CD, Piawah S, Van Loon K, Bainter TM, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg R, O'Reilly EM, Meyerhardt JA, Ng K| | View in PubMed
Colorectal Cancer Surveillance With Circulating Tumor DNA Assay.
Quality of life of colorectal cancer survivors participating in a pilot randomized controlled trial of physical activity trackers and daily text messages.
Chan H, Van Loon K, Kenfield SA, Chan JM, Mitchell E, Zhang L, Paciorek A, Joseph G, Laffan A, Atreya C, Fukuoka Y, Miaskowski C, Meyerhardt JA, Venook AP, Van Blarigan EL| | View in PubMed
Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer.
Van Blarigan EL, Ou FS, Bainter TM, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Hantel A, Benson AB, Atienza D, Messino M, Kindler HL, Venook AP, Ogino S, Sanoff HK, Giovannucci EL, Ng K, Meyerhardt JA| | View in PubMed
Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.
Yothers G, Venook AP, Oki E, Niedzwiecki D, Lin Y, Crager MR, Chao C, Baehner FL, Wolmark N, Yoshino T| | View in PubMed
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.
Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.
Papamichael D, Lopes GS, Olswold CL, Douillard JY, Adams RA, Maughan TS, Van Cutsem E, Venook AP, Lenz HJ, Heinemann V, Kaplan R, Bokemeyer C, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, De Gramont A, Shi Q| | View in PubMed
Feasibility and Acceptability of a Physical Activity Tracker and Text Messages to Promote Physical Activity During Chemotherapy for Colorectal Cancer: Pilot Randomized Controlled Trial (Smart Pace II).
Van Blarigan EL, Dhruva A, Atreya CE, Kenfield SA, Chan JM, Milloy A, Kim I, Steiding P, Laffan A, Zhang L, Piawah S, Fukuoka Y, Miaskowski C, Hecht FM, Kim MO, Venook AP, Van Loon K| | View in PubMed
Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.
Yin J, Cohen R, Jin Z, Liu H, Pederson L, Adams R, Grothey A, Maughan TS, Venook A, Van Cutsem E, Punt C, Koopman M, Falcone A, Tebbutt NC, Seymour MT, Bokemeyer C, Rubio ED, Kaplan R, Heinemann V, Chibaudel B, Yoshino T, Zalcberg J, Andre T, De Gramont A, Shi Q, Lenz HJ| | View in PubMed
Being Present 2.0: Online Mindfulness-Based Program for Metastatic Gastrointestinal Cancer Patients and Caregivers.
Dragomanovich HM, Dhruva A, Ekman E, Schoenbeck KL, Kubo A, Van Blarigan EL, Borno HT, Esquivel M, Chee B, Campanella M, Philip EJ, Rettger JP, Rosenthal B, Van Loon K, Venook AP, Boscardin C, Moran P, Hecht FM, Atreya CE| | View in PubMed
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer.
Arai H, Elliott A, Millstein J, Xiu J, Ou FS, Innocenti F, Wang J, Battaglin F, Jayachandran P, Kawanishi N, Soni S, Zhang W, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Lockhart AC, Shields AF, Abraham JP, Magee D, Stafford P, Zhang J, Venook AP, Korn WM, Lenz HJ| | View in PubMed
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
Quintanilha JCF, Wang J, Sibley AB, Xu W, Espin-Garcia O, Jiang C, Etheridge AS, Ratain MJ, Lenz HJ, Bertagnolli M, Kindler HL, Dickler MN, Venook A, Liu G, Owzar K, Lin D, Innocenti F| | View in PubMed
BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.
Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931).
Snyder RA, He J, Le-Rademacher J, Ou FS, Dodge AB, Zemla TJ, Paskett ED, Chang GJ, Innocenti F, Blanke C, Lenz HJ, Polite BN, Venook AP| | View in PubMed
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis.
Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, Hurwitz H, Punt C, Diaz Rubio E, Koopman M, Cremolini C, Heinemann V, Tournigard C, Bokemeyer C, Fuchs C, Tebbutt N, Souglakos J, Doulliard JY, Kabbinavar F, Chibaudel B, de Gramont A, Shi Q, Grothey A, Adams R| | View in PubMed
Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Frankel WL, Niedzwiecki D, Noonan A, Janjigian YY, Thurmes PJ, Venook AP, Meyerhardt JA, O'Reilly EM, Ilson DH| | View in PubMed
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, D'Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, Chahal P, Chang DT, Cloyd J, Covey AM, Glazer ES, Goyal L, Hawkins WG, Iyer R, Jacob R, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Sahai V, Schefter T, Singh G, Stein S, Vauthey JN, Venook AP, Yopp A, McMillian NR, Hochstetler C, Darlow SD| | View in PubMed
Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance).
Lee S, Zhang S, Ma C, Ou FS, Wolfe EG, Ogino S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Gross CP, Irwin ML, Meyerhardt JA, Fuchs CS| | View in PubMed
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF| | View in PubMed
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA| | View in PubMed
Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.
Abraham JP, Magee D, Cremolini C, Antoniotti C, Halbert DD, Xiu J, Stafford P, Berry DA, Oberley MJ, Shields AF, Marshall JL, Salem ME, Falcone A, Grothey A, Hall MJ, Venook AP, Lenz HJ, Helmstetter A, Korn WM, Spetzler DB| | View in PubMed
Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer.
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
Innocenti F, Sibley AB, Patil SA, Etheridge AS, Jiang C, Ou FS, Howell SD, Plummer SJ, Casey G, Bertagnolli MM, McLeod HL, Auman JT, Blanke CD, Furukawa Y, Venook AP, Kubo M, Lenz HJ, Parker JS, Ratain MJ, Owzar K| | View in PubMed
IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405.
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL| | View in PubMed
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S| | View in PubMed
NCCN Guidelines Insights: Rectal Cancer, Version 6.2020.
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hoffe S, Hubbard J, Hunt S, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gurski LA| | View in PubMed
Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients.
Susko M, Wang CJ, Lazar AA, Kim S, Laffan A, Feng M, Ko A, Venook AP, Atreya CE, Van Loon K, Anwar M| | View in PubMed
A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.
El Dika I, Mayer RJ, Venook AP, Capanu M, LaQuaglia MP, Kobos R, O'Neill AF, Chou JF, Ly M, Ang C, O'Reilly EM, Gordan JD, Abou-Alfa GK| | View in PubMed
Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405.
Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
Abou-Alfa GK, Mayer R, Venook AP, O'Neill AF, Beg MS, LaQuaglia M, Kingham PT, Kobos R, Basturk O, Brennan C, Yopp A, Harding JJ, Leong S, Crown J, Hoti E, Leonard G, Ly M, Bradley M, Valentino E, Markowitz D, Zukiwski A, Ren K, Gordan JD| | View in PubMed
Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer.
Ursem C, Zhou M, Paciorek A, Atreya CE, Ko AH, Venook A, Zhang L, Van Loon K| | View in PubMed
Feasibility and Acceptability of a Web-Based Dietary Intervention with Text Messages for Colorectal Cancer: A Randomized Pilot Trial.
Van Blarigan EL, Kenfield SA, Chan JM, Van Loon K, Paciorek A, Zhang L, Chan H, Savoie MB, Bocobo AG, Liu VN, Wong LX, Laffan A, Atreya CE, Miaskowski C, Fukuoka Y, Meyerhardt JA, Venook AP| | View in PubMed
Heated Intraperitoneal Chemotherapy for Colorectal Carcinomatosis: Emerging Evidence.
Snyder RA, Fournier K, Royal R, Venook AP, Chang GJ| | View in PubMed
Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.
Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K| | View in PubMed
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.
Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JJ, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP| | View in PubMed
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance).
Brown JC, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Denlinger CS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA| | View in PubMed
Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).
Yuan C, Sato K, Hollis BW, Zhang S, Niedzwiecki D, Ou FS, Chang IW, O'Neil BH, Innocenti F, Lenz HJ, Blanke CD, Goldberg RM, Venook AP, Mayer RJ, Fuchs CS, Meyerhardt JA, Ng K| | View in PubMed
Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski LA| | View in PubMed
Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.
Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK| | View in PubMed
Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer.
Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA| | View in PubMed
Vitamin D Levels in Patients with Colorectal Cancer and Matched Household Members.
Savoie MB, Paciorek A, Zhang L, Sommovilla N, Venook AP, Van Blarigan EL, Van Loon K| | View in PubMed
High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.
Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, Anders R, Are C, Brown D, Chang DT, Cloyd J, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Hammond LJ, Darlow SD| | View in PubMed
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O| | View in PubMed
Self-monitoring and reminder text messages to increase physical activity in colorectal cancer survivors (Smart Pace): a pilot randomized controlled trial.
Van Blarigan EL, Chan H, Van Loon K, Kenfield SA, Chan JM, Mitchell E, Zhang L, Paciorek A, Joseph G, Laffan A, Atreya CE, Fukuoka Y, Miaskowski C, Meyerhardt JA, Venook AP| | View in PubMed
Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).
Morales-Oyarvide V, Yuan C, Babic A, Zhang S, Niedzwiecki D, Brand-Miller JC, Sampson-Kent L, Ye X, Li Y, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Wolpin BM, Meyerhardt JA, Fuchs CS, Ng K| | View in PubMed
Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance).
Schrag D, Weiser M, Saltz L, Mamon H, Gollub M, Basch E, Venook A, Shi Q| | View in PubMed
Genetic variation determines VEGF-A plasma levels in cancer patients.
A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK| | View in PubMed
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
Innocenti F, Owzar K, Jiang C, Etheridge AS, Gordân R, Sibley AB, Mulkey F, Niedzwiecki D, Glubb D, Neel N, Talamonti MS, Bentrem DJ, Seiser E, Yeh JJ, Van Loon K, McLeod H, Ratain MJ, Kindler HL, Venook AP, Nakamura Y, Kubo M, Petersen GM, Bamlet WR, McWilliams RR| | View in PubMed
Being Present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers.
Atreya CE, Kubo A, Borno HT, Rosenthal B, Campanella M, Rettger JP, Joseph G, Allen IE, Venook AP, Altschuler A, Dhruva A| | View in PubMed
Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance).
Van Blarigan EL, Ou FS, Niedzwiecki D, Zhang S, Fuchs CS, Saltz L, Mayer RJ, Venook A, Ogino S, Song M, Benson A, Hantel A, Atkins JN, Giovannucci EL, Meyerhardt JA| | View in PubMed
Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance).
Guercio BJ, Zhang S, Niedzwiecki D, Li Y, Babic A, Morales-Oyarvide V, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Zoltick ES, Stampfer M, Ng K, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS| | View in PubMed
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA| | View in PubMed
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA| | View in PubMed
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).
Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL| | View in PubMed
Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial.
Van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Ng K, Meyerhardt JA| | View in PubMed
Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
Brown JC, Zhang S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Li Y, Zhang X, Ng K, Willett WC, Giovannucci EL, Fuchs CS, Meyerhardt JA| | View in PubMed
Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer.
Snyder RA, Hu CY, Cuddy A, Francescatti AB, Schumacher JR, Van Loon K, You YN, Kozower BD, Greenberg CC, Schrag D, Venook A, McKellar D, Winchester DP, Chang GJ, Alliance for Clinical Trials in Oncology Network Cancer Surveillance Optimization Working Group| | View in PubMed
Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer.
NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA| | View in PubMed
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
Fadelu T, Zhang S, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson AB, Atienza DM, Messino M, Kindler HL, Venook A, Ogino S, Ng K, Wu K, Willett W, Giovannucci E, Meyerhardt J, Bao Y, Fuchs CS| | View in PubMed
Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance).
Van Blarigan EL, Fuchs CS, Niedzwiecki D, Ye X, Zhang S, Song M, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Meyerhardt JA| | View in PubMed
The Developing Role of Anti-Epidermal Growth Factor Receptor Agents in the Treatment of Advanced or Metastatic Colorectal Cancer.
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ| | View in PubMed
Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance).
McCleary NJ, Hubbard J, Mahoney MR, Meyerhardt JA, Sargent D, Venook A, Grothey A| | View in PubMed
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D| | View in PubMed
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F| | View in PubMed
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).
Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Innocenti F, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K| | View in PubMed
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.
Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S| | View in PubMed
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D| | View in PubMed
Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy.
Tantoy IY, Dhruva A, Cataldo J, Venook A, Cooper BA, Paul SM, Levine JD, Conley YP, Cartwright F, Lee K, Wright F, Miaskowski C| | View in PubMed
Reply to L. Casadaban et al.
Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F| | View in PubMed
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
Parikh A, Atreya C, Korn WM, Venook AP| | View in PubMed
Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.
Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ| | View in PubMed
Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.
Atreya CE, Greene C, McWhirter RM, Ikram NS, Allen IE, Van Loon K, Venook AP, Yeh BM, Behr SC| | View in PubMed
Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.
Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP| | View in PubMed
Role of Biologics in Colon Cancer: Still Not Clear.
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK| | View in PubMed
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP| | View in PubMed
Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, Bowers DL, Pang H, Owzar K, Niedzwiecki D, Innocenti F, Venook AP, Hurwitz HI, Nixon AB, Alliance for Clinical Trials in Oncology| | View in PubMed
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F| | View in PubMed
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, Goldberg RM| | View in PubMed
Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer.
Kober KM, Dunn L, Mastick J, Cooper B, Langford D, Melisko M, Venook A, Chen LM, Wright F, Hammer M, Schmidt BL, Levine J, Miaskowski C, Aouizerat BE| | View in PubMed
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL| | View in PubMed
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.
Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM| | View in PubMed
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S| | View in PubMed
Subgroups of chemotherapy patients with distinct morning and evening fatigue trajectories.
Kober KM, Cooper BA, Paul SM, Dunn LB, Levine JD, Wright F, Hammer MJ, Mastick J, Venook A, Aouizerat BE, Miaskowski C| | View in PubMed
The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
Guercio BJ, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Hu FB, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS| | View in PubMed
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM| | View in PubMed
On the Verge: Immunotherapy for Colorectal Carcinoma.
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD| | View in PubMed
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS| | View in PubMed
Bone metastases and skeletal-related events from neuroendocrine tumors.
Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK| | View in PubMed
Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).
Lamont EB, Schilsky RL, He Y, Muss H, Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R, Niell H, Goldberg RM, Joffe S, Alliance for Clinical Trials in Oncology| | View in PubMed
Progression-free survival: helpful biomarker or clinically meaningless end point?
NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.
Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML| | View in PubMed
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ| | View in PubMed
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).
Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O'Reilly EM, Fuchs C, Innocenti F, Venook AP, Alliance for Clinical Trials in Oncology| | View in PubMed
Hepatobiliary cancers, version 2.2014.
Benson AB, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H| | View in PubMed
Colon cancer, version 3.2014.
Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA, National Comprehensive Cancer Network| | View in PubMed
Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance).
Fuchs MA, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA| | View in PubMed
90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.
Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP| | View in PubMed
CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM, Alliance for Clinical Trials in Oncology| | View in PubMed
International adaptations of NCCN Clinical Practice Guidelines in Oncology.
Carlson RW, Larsen JK, McClure J, Fitzgerald CL, Venook AP, Benson AB, Anderson BO| | View in PubMed
Progress against GI cancer during the American Society of Clinical Oncology's first 50 years.
Mayer RJ, Venook AP, Schilsky RL| | View in PubMed
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.
Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE| | View in PubMed
Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities.
Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines.
Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA, National Comprehensive Cancer Network| | View in PubMed
Predictive biomarkers for bevacizumab: are we there yet?
Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM| | View in PubMed
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP| | View in PubMed
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.
Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM, Pisters PW, Posner MC, Berlin JD, Ahmad SA| | View in PubMed
Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines.
Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA| | View in PubMed
Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405.
Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM| | View in PubMed
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Venook A, Fuchs CS| | View in PubMed
Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain.
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA| | View in PubMed
When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
Is there currently an established role for the use of predictive or prognostic molecular markers in the management of colorectal cancer? A point/counterpoint.
Venook AP, Bendell JC, Warren RS| | View in PubMed
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303).
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.
Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A| | View in PubMed
Hepatocellular carcinoma: Ablate and wait versus rapid transplantation.
Roberts JP, Venook A, Kerlan R, Yao F| | View in PubMed
Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
Lencioni R, Marrero J, Venook A, Ye SL, Kudo M| | View in PubMed
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP, American Hepato-Pancreato-Biliary Association, Society of Surgical Oncology, Society for Surgery of the Alimentary Tract| | View in PubMed
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB| | View in PubMed
Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK| | View in PubMed
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA| | View in PubMed
NCCN clinical practice guidelines in oncology. Anal carcinoma.
Engstrom PF, Arnoletti JP, Benson AB, Berlin JD, Berry JM, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E, Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM, Small W, Sofocleous C, Thomas J, Venook AP, Willett C, NCCN| | View in PubMed
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective.
Venook AP, Papandreou C, Furuse J, de Guevara LL| | View in PubMed
Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA| | View in PubMed
Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
NCCN Task Force Report: mTOR inhibition in solid tumors.
Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y| | View in PubMed
The impact of new data in the treatment of advanced hepatocellular carcinoma.
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA| | View in PubMed
Responding to the rising incidence of hepatocellular carcinoma with targeted therapy.
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA| | View in PubMed
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L| | View in PubMed
Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology.
Goldberg RM, Marshall JL, Ajani JA, Philip PA, O'Reilly EM, Venook AP| | View in PubMed
Colon cancer.
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Fakih MG, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saltz L, Shibata D, Skibber JM, Venook AP, Fox Chase Cancer Center Partners| | View in PubMed
Rectal cancer.
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Fakih MG, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saltz L, Shibata D, Skibber JM, Venook AP, National Comprehensive Cancer Network| | View in PubMed
Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L| | View in PubMed
An alternative therapy for patients with hepatic impairment?
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ| | View in PubMed
End points in advanced colon cancer clinical trials: a review and proposal.
Allegra C, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol NJ, Saltz L, Venook A, Yothers G, Sargent D| | View in PubMed
Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis.
Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME| | View in PubMed
Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
Nakakura EK, Venook AP, Bergsland EK| | View in PubMed
Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.
Venook AP, Blanke CD, Niedzwiecki D, Lenz HJ, Taylor JR, Hollis DR, Sutherland S, Goldberg RM| | View in PubMed
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA| | View in PubMed
Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver.
Qayyum A, Lee GK, Yeh BM, Allen JN, Venook AP, Coakley FV| | View in PubMed
Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement.
Bartlett DL, Berlin J, Lauwers GY, Messersmith WA, Petrelli NJ, Venook AP| | View in PubMed
Hepatobiliary cancers. Clinical practice guidelines in oncology.
Benson AB, Bekaii-Saab T, Ben-Josef E, Blumgart L, Clary BM, Curley SA, Davila R, Earle CC, Ensminger WD, Gibbs JF, Laheru D, Langnas AN, Mulvihill SJ, Nemcek AA, Posey JA, Sigurdson ER, Sinanan M, Vauthey JN, Venook AP, Wagman LD, Yeatman TJ, National Comprehensive Cancer Network| | View in PubMed
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA| | View in PubMed
Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
Venook AP, Blanke CD, Niedzwiecki D, Lenz HJ, Taylor JR, Hollis DR, Sutherland S, Goldberg RM| | View in PubMed
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA| | View in PubMed
Anal canal cancer clinical practice guidelines in oncology.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer Network| | View in PubMed
Colon cancer clinical practice guidelines in oncology.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer Network| | View in PubMed
Rectal cancer clinical practice guidelines in oncology.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer Network| | View in PubMed
Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma.
The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma.
Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R, Kerlan R, Venook A, Ascher NL, Emond JC, Roberts JP| | View in PubMed
Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.
Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland EK, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM| | View in PubMed
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.
Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA| | View in PubMed
Cetuximab in the treatment of colorectal cancer.
Goldberg RM, Venook AP, Schilsky RL| | View in PubMed
Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite--initial experience with four patients.
Wilson MW, Kerlan RK, Fidelman NA, Venook AP, LaBerge JM, Koda J, Gordon RL| | View in PubMed
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D| | View in PubMed
A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
Wilkinson MJ, Frye JW, Small EJ, Venook AP, Carroll PR, Ernest ML, Stagg RJ| | View in PubMed
The Sweet syndrome during therapy with granulocyte colony-stimulating factor.
Park JW, Mehrotra B, Barnett BO, Baron AD, Venook AP| | View in PubMed
Hepatic cancers and their response to chemoembolization therapy. Quantitative image-guided 31P magnetic resonance spectroscopy.
Meyerhoff DJ, Karczmar GS, Valone F, Venook A, Matson GB, Weiner MW| | View in PubMed
Hepatic intra-arterial methylene blue injection during endoscopy: a method of detecting gastroduodenal misperfusion in patients receiving hepatic intra-arterial chemotherapy via an implanted pump.
Frye JW, Venook AP, Ostroff JW, Mulvihill SJ, Warren RS, Pellegrini CA, Ring EJ, Stagg RJ| | View in PubMed
Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer.
Stagg RJ, Venook AP, Chase JL, Lewis BJ, Warren RS, Roh M, Mulvihill SJ, Grobman BJ, Rayner AA, Hohn DC| | View in PubMed
Chemoembolization for hepatocellular carcinoma.
Venook AP, Stagg RJ, Lewis BJ, Chase JL, Ring EJ, Maroney TP, Hohn DC| | View in PubMed
Activity of coumarin and cimetidine in metastatic renal cell carcinoma.
